Trial Profile
Safety and Efficacy of Iloprost and Eptifibatide Co-administration Compared to Standard Therapy in Patients With Septic Shock - a Randomized, Controlled, Double-blind Investigator-initiated Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptifibatide (Primary) ; Iloprost (Primary)
- Indications Sepsis; Septic shock
- Focus Biomarker; Therapeutic Use
- Acronyms CO-ILEPSS
- 21 Apr 2017 Status changed from recruiting to completed.
- 26 Aug 2016 This trial was completed in Denmark (end date: 11 Aug 2016).
- 01 Aug 2014 New trial record